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The current health-care philosophy dictates that new
therapies should always be evaluated for their economic
impact. Along with acquisition cost, the cost of delivery,
monitoring, adverse effects and treatment failure must
also be considered when determining the total cost of
therapy.
OBJECTIVE: The purpose of this study was to evaluate
the efficacy, safety, and cost of vancomycin and teicopla-
nin therapy in patients with neutropenia, after the failure
of empirical treatment with a combination of piperacillin-
tazobactam an amikacin.
METHODS: 76 febrile episodes with haematological ma-
lignancies, neutropenia, and resistant fever to the combi-
nation piperaciline-tazobactam and amikacin were ran-
domised to receive either teicoplanin or vancomycin.
Evaluation of clinical efficacy depended on whether or
not apyrexia was obtained after 48 hours, after 7 days, or
at conclusion of aplasia. In the cost analysis we have con-
sidered the following partial costs: drug price, prepara-
tion and administration cost, monitoring costs, treatment
of adverse events, and treatment failure.
RESULTS: Primary success of second-line therapy was
obtained in 35 cases (46%) with no significant difference
between vancomycin (17/38) and teicoplanin arms (18/
38). No differences in renal or hepatic toxicity related to
the antibiotic therapy were observed. The average cost
per patient according to glycopeptide used was $450
(180) for the teicoplanin group and $473 (347) for the
vancomycin group; no significant differences were found
in the total cost.
CONCLUSION: Our pharmacoeconomic analysis dem-
onstrated that teicoplanin and vancomycin can be admin-
istered in neutropenic haematology patients with similar
efficacy and direct costs.
